Last reviewed · How we verify

Amlodipine low — Competitive Intelligence Brief

Amlodipine low (Amlodipine low) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

phase 2 Calcium channel blocker L-type calcium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Amlodipine low (Amlodipine low) — Addpharma Inc.. Amlodipine is a calcium channel blocker that works by relaxing blood vessels and reducing blood pressure.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Amlodipine low TARGET Amlodipine low Addpharma Inc. phase 2 Calcium channel blocker L-type calcium channels
Losartan and amlodipine and hydrochlorothiazide Losartan and amlodipine and hydrochlorothiazide Hotel Dieu de France Hospital marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter
Calcium Channel Blockers, ACE-Inhibitor Calcium Channel Blockers, ACE-Inhibitor University of Aarhus marketed Combination antihypertensive (calcium channel blocker + ACE inhibitor) L-type calcium channels; Angiotensin-converting enzyme (ACE)
Nicardipine + Verapamil + Nitroglycerin Nicardipine + Verapamil + Nitroglycerin Peng Roc Chen, MD marketed Combination antihypertensive/antianginal (calcium channel blockers + nitrate) L-type calcium channels (nicardipine, verapamil); soluble guanylate cyclase (nitroglycerin)
olmesartan/amlodipine + hydrochlorothiazide, if necessary. olmesartan/amlodipine + hydrochlorothiazide, if necessary. Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company marketed Antihypertensive combination (ARB + calcium channel blocker + thiazide diuretic) Angiotensin II type 1 receptor (AT1R), L-type calcium channels, sodium-chloride cotransporter (NCC)
Norvasc Amlodipine Besylate Pfizer Inc. marketed Dihydropyridine calcium channel antagonist L-type calcium channels
Nicardipine , Esmolol Nicardipine , Esmolol Nanjing Medical University marketed Calcium channel blocker + Beta-1 selective adrenergic antagonist combination L-type calcium channels; Beta-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

  1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
  2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  3. Ain Shams University · 1 drug in this class
  4. Bioprojet · 1 drug in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Handok Inc. · 1 drug in this class
  8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
  9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
  10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Amlodipine low — Competitive Intelligence Brief. https://druglandscape.com/ci/amlodipine-low. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: